Department of Physical Therapy, School of Health and Human Sciences, Indiana University, Indianapolis, IN, United States; Indiana Center for Musculoskeletal Health, Indiana University, Indianapolis, IN, United States; La Trobe Sport and Exercise Medicine Research Centre, La Trobe University, Bundoora, Victoria, Australia.
Department of Physical Therapy, School of Health and Human Sciences, Indiana University, Indianapolis, IN, United States.
Gait Posture. 2019 Oct;74:83-86. doi: 10.1016/j.gaitpost.2019.08.020. Epub 2019 Aug 28.
There is a clinical need to be able to reliably detect meaningful changes (0.1 to 0.2 m/s) in usual gait speed (UGS) considering reduced gait speed is associated with morbidity and mortality.
What is the impact of tester on UGS assessment, and the influence of test repetition (trial 1 vs. 2), timing method (manual stopwatch vs. automated timing), and starting condition (stationary vs. dynamic start) on the ability to detect changes in UGS and fast gait speed (FGS)?
UGS and FGS was assessed in 725 participants on a 8-m course with infrared timing gates positioned at 0, 2, 4 and 6 m. Testing was performed by one of 13 testers trained by a single researcher. Time to walk 4-m from a stationary start (i.e. from 0-m to 4-m) was measured manually using a stopwatch and automatically via the timing gates at 0-m and 4-m. Time taken to walk 4-m with a dynamic start was measured during the same trial by recording the time to walk between the timing gates at 2-m and 6-m (i.e. after 2-m acceleration).
Testers differed for UGS measured using manual vs. automated timing (p = 0.02), with five and two testers recording slower and faster UGS using manual timing, respectively. 95% limits of agreement for trial 1 vs. 2, manual vs. automated timing, and dynamic vs. stationary start ranged from ±0.15 m/s to ±0.20 m/s, coinciding with the range for a clinically meaningful change. Limits of agreement for FGS were larger ranging from ±0.26 m/s to ±0.35 m/s.
Repeat testing of UGS should performed by the same tester or using an automated timing method to control for tester effects. Test protocol should remain constant both between and within participants as protocol deviations may result in detection of an artificial clinically meaningful change.
鉴于步态速度降低与发病率和死亡率相关,因此临床上需要能够可靠地检测到通常步态速度(UGS)的有意义变化(0.1 至 0.2m/s)。
测试者对 UGS 评估的影响,以及测试重复(试验 1 与试验 2)、计时方法(手动秒表与自动计时)和起始条件(静止与动态起始)对检测 UGS 和快速步态速度(FGS)变化能力的影响。
在一条 8 米长的赛道上,使用红外线计时门在 0、2、4 和 6m 处定位,对 725 名参与者进行 UGS 和 FGS 评估。测试由经过一名研究人员培训的 13 名测试者之一进行。手动使用秒表和自动通过计时门在 0m 和 4m 处测量从静止开始行走 4m 的时间(即从 0m 到 4m)。使用动态起始测量 4m 所需的时间是在同一次试验中通过记录计时门在 2m 和 6m 之间(即 2m 加速后)行走的时间来测量的。
测试者对使用手动与自动计时测量的 UGS 有差异(p=0.02),分别有五名和两名测试者使用手动计时记录了较慢和较快的 UGS。试验 1 与试验 2、手动与自动计时、动态与静止起始之间的 95%一致性界限在±0.15m/s 至±0.20m/s 之间,与临床有意义变化的范围一致。FGS 的一致性界限较大,范围在±0.26m/s 至±0.35m/s 之间。
应通过同一名测试者或使用自动计时方法重复测试 UGS,以控制测试者的影响。测试方案应在参与者之间和内部保持一致,因为方案偏差可能导致检测到人为的临床有意义的变化。